A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Decitabine/Cedazuridine

Oral FDC tablets administration

DRUG

Magrolimab

IV administration

Trial Locations (3)

BRCR Medical Center, Plantation

Masonic Cancer Center, University of Minnesota, Minneapolis

Yale University, New Haven